Patrick J. Heron - Sep 11, 2023 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)

Role
Director
Signature
/s/ Steve R. Bailey, as Attorney-in-Fact
Stock symbol
MIRM
Transactions as of
Sep 11, 2023
Transactions value $
$256,791
Form type
4
Date filed
9/13/2023, 04:39 PM
Previous filing
Sep 5, 2023
Next filing
Sep 15, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MIRM Common Stock Purchase $142K +4.69K +3.17% $30.30 153K Sep 11, 2023 By Frazier Life Sciences X, L.P. F1, F2
transaction MIRM Common Stock Purchase $115K +3.75K +2.46% $30.60 156K Sep 12, 2023 By Frazier Life Sciences X, L.P. F2, F3
holding MIRM Common Stock 3.57M Sep 11, 2023 By Frazier Life Sciences IX, L.P. F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $30.0968 to $30.4835, inclusive. The Reporting Person undertakes to provide to Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (3) to this Form 4.
F2 The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person and James N. Topper are the managing members of FHMLS X, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences X, L.P. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein.
F3 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $30.2781 to $30.7970, inclusive.
F4 The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. The Reporting Person and James N. Topper are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein.